Vosseller Leigh 4

What Happened

• Leigh Vosseller, Chief Financial Officer of Tandem Diabetes Care, received a grant of 62,657 restricted stock units (RSUs) on 2026-05-29. The Form 4 reports this as an award/derivative grant with an acquisition price of $0, reflecting a compensation grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-02 (appears to be filed within the two-business-day window).
• Grant details: 62,657 RSUs; reported acquisition price $0 (derivative award).
• Vesting (per footnotes): one-third vests on 5/29/2027; remaining RSUs vest in eight equal quarterly installments on the 15th of the month thereafter, subject to the 2023 Long-Term Incentive Plan.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Remarks/attachments: Exhibit 24 (Power of Attorney) noted on the filing.

Context

• RSUs are a compensation award that convert into shares (or cash in lieu, at the company’s discretion) if and when vesting conditions are met; they are common executive compensation and do not represent an immediate purchase signal to the market.
• Because this is an awarded grant (not a purchase or sale), it’s primarily informative about management compensation and potential future share issuance once vesting occurs.